In pharmacy news:

The largest U.S. pharmacy benefit manager, Express Scripts, said on Monday it has lined up a cheaper price for AbbVie Inc’s newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences’ Sovaldi treatments, after trying for nearly a year to win a deeper discount. Express Scripts’ move reignited investor concerns that pharmaceutical companies will have to bow to pricing pressure from U.S. insurers and lawmakers over novel medications whose cost can reach hundreds of thousands of dollars for some diseases.

Read the full report from Reuters here.

Leave a Comment

Your email address will not be published. Required fields are marked *